Overview

• TikTok and Meta removed posts and blocked related hashtags after investigations flagged videos with mixing guides, testimonials and sales pitches.
• Eli Lilly says any sales for human use are illegal, while the UK’s MHRA warns products claiming to contain retatrutide are likely unlawful and dangerous.
• The investigational triple-agonist remains in phase 3 trials with availability projected no sooner than late 2026 in the U.S., potentially 2027.
• A persistent gray market sells research-lab powders labeled “retatrutide” that users reconstitute and inject, with influencers and some resellers promoting the products.
• Regulators cite seizures, arrests and border interceptions tied to counterfeit GLP-1s and warn of inconsistent dosing, contamination and serious adverse effects.